Morgan Stanley decreased its stake in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 27.2% during the first quarter, according to its most recent filing with the SEC. The fund owned 92,624 shares of the company’s stock after selling 34,577 shares during the period. Morgan Stanley’s holdings in Aerie Pharmaceuticals were worth $4,201,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. First Mercantile Trust Co. boosted its stake in shares of Aerie Pharmaceuticals by 29.9% in the first quarter. First Mercantile Trust Co. now owns 7,031 shares of the company’s stock worth $319,000 after buying an additional 1,620 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Aerie Pharmaceuticals during the first quarter worth about $107,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Aerie Pharmaceuticals during the first quarter worth about $108,000. Teachers Advisors LLC boosted its stake in shares of Aerie Pharmaceuticals by 5.1% in the first quarter. Teachers Advisors LLC now owns 49,726 shares of the company’s stock worth $2,255,000 after buying an additional 2,402 shares during the last quarter. Finally, Fox Run Management L.L.C. boosted its stake in shares of Aerie Pharmaceuticals by 49.3% in the first quarter. Fox Run Management L.L.C. now owns 9,558 shares of the company’s stock worth $433,000 after buying an additional 3,158 shares during the last quarter. 92.98% of the stock is currently owned by hedge funds and other institutional investors.

Aerie Pharmaceuticals, Inc. (NASDAQ AERI) traded down 2.14% on Friday, reaching $50.35. 476,944 shares of the company’s stock traded hands. The company’s 50 day moving average is $54.55 and its 200-day moving average is $48.00. Aerie Pharmaceuticals, Inc. has a 52-week low of $18.35 and a 52-week high of $59.50. The stock’s market cap is $1.83 billion.

Aerie Pharmaceuticals (NASDAQ:AERI) last announced its quarterly earnings data on Tuesday, August 1st. The company reported ($0.82) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.02. Equities analysts expect that Aerie Pharmaceuticals, Inc. will post ($2.56) EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/13/morgan-stanley-has-4-20-million-stake-in-aerie-pharmaceuticals-inc-nasdaqaeri.html.

A number of equities research analysts have recently issued reports on AERI shares. HC Wainwright reaffirmed a “buy” rating and issued a $69.00 target price on shares of Aerie Pharmaceuticals in a report on Wednesday, May 3rd. Needham & Company LLC upped their target price on shares of Aerie Pharmaceuticals from $58.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, May 25th. Cowen and Company reaffirmed an “outperform” rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Tuesday, April 18th. Canaccord Genuity set a $56.00 target price on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 22nd. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Friday, July 28th. One analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $66.08.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of Aerie Pharmaceuticals stock in a transaction dated Friday, May 26th. The shares were sold at an average price of $55.95, for a total value of $1,119,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 9.36% of the company’s stock.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.